| Similar Articles |
|---|
 |
Bio-IT World
March 8, 2005
John Russell |
Entelos' Lofty Aspirations This is an interesting period for systems biology's wing of predictive biology companies. The label's luster is fading, but buoyed by pharma's growing interest, they are trying to figure out how to grow.   |
Bio-IT World
November 12, 2002
Michael Goldman |
A Virtual Pharmacopeia Computational modeling of disease pathways, organs --- even patients --- could transform drug discovery. Does salvation exist in silico? |
Bio-IT World
February 2006
John Russell |
Marvelous Models of Biological Systems Here are highlights from a roundtable discussion with researchers representing academia and pharmaceuticals, as well as executives from modeling technology providers on whether or not Pharma is ready to bet on computational modeling of biological systems. |
Bio-IT World
May 19, 2004
John Russell |
Seeing the Forest and the Trees A tiny clearing in the fog of systems biology. |
Bio-IT World
September 2006
John Russell |
Predicting the Future of Systems Biology Buoyed by promising results from a recent collaboration with Pfizer on drug-induced vascular injury, Keith Elliston, CEO of modeling and biosimulation specialist Genstruct, offers a candid view of industry's flirtation with systems biology and the future prospects for the field. |
Bio-IT World
August 18, 2004
Mark D. Uehling |
I, Virtual Patient Along with a software company specializing in modeling diseases on the computer, Roche Diagnostics is working on creating a new biomarker for diabetes that could be reduced to a simple blood test. |
Bio-IT World
January 21, 2005 |
Defining 'Integrative Genomics' Five experts from academia and industry discuss the burgeoning field of integrative genomics. |
Bio-IT World
September 2006
John Russell |
Informatics Cornucopia Predictive Informatics, the hopeful title of a session at last month's Drug Discovery Technology & Development World Congress, remains an enticing but mostly elusive goal. Asked what systems biology would look in five years and what will constitute success, panelists offered the following. |
Bio-IT World
December 15, 2003
Mark D. Uehling |
Model Patient Despite the FDA's new support for computational modeling, the pharmaceutical industry remains cautious about simulating clinical trials. |
Bio-IT World
October 2006
John Russell |
GNS Charts "Unknown" Biology Gene Network Sciences' CEO and colleagues now think they have the right tool to mine the treasure trove of unknown biology hidden in the wealth of accumulating omic data. |
CIO
October 15, 2001
Stephanie Overby |
Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age... |
Bio-IT World
July 14, 2004
Malorye A. Branca |
The Pathways Promise By using the right tools, even a modest genomic data set can generate a good view into a particular biological pathway. Now, a range of new technologies is arising from academia as well as the commercial sector to meet this need. |
Bio-IT World
Dec 2006/Jan 2007
John Russell |
Setting the Systems Bio Syllabus An interview with David de Graaf about Pfizer's growing comfort with systems biology. |
Pharmaceutical Executive
February 1, 2006
Ron Feemster |
Gene Logic: Rescue Squad One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets. |
Bio-IT World
February 2006
John Russell |
Preventable Vioxx Problems? Pathway analysis tools might have identified Vioxx's problematic off-target activity much earlier. Wondering which modeling approach to use for your project? |
Bio-IT World
September 16, 2004
Michael A. Greeley |
Platforms for Pathways Investor interest in the next great blockbuster drug has been blistering hot; Phase II and Phase III compound companies are being funded at a near record-breaking pace now that the IPO window seems to be slightly open |
Bio-IT World
October 14, 2004
Zachary Zimmerman |
Follow the Pathway to Increased ROI Although this software has been commercially available for only a year, Ingenuity claims nine of the top 10 pharmaceutical companies as customers, including Pfizer, Wyeth, GlaxoSmithKline, and Aventis. |
Bio-IT World
December 15, 2003
Zachary Zimmerman |
Learning the Language of Systems Biology Geneticist par excellence David Botstein talks about his philosophy, science, his mission for integrative science, and what he deems a success for systems biology. |
Bio-IT World
March 2006
John Russell |
It's All About the Drugs A conversation with biopharma Organon's executive VP for global research and development highlights how, regardless of the company's enthusiasm for new technology, it is first and foremost interested in pharmacology and medicinal chemistry -- drugs. |
Bio-IT World
October 14, 2004 |
Deciphering Genstruct If you divide the systems biology world into two broad camps, wet-lab-focused data generators and in silico model makers, Genstruct is a modeler with a twist. |
Bio-IT World
November 12, 2002
James Golden |
The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success. |
Bio-IT World
August 18, 2004 |
Project Summaries Drug Discovery and Development: Ace BioSciences... Compugen... Entelos/Organon... Iconix Pharmaceuticals... Johnson & Johnson Pharmaceutical Research & Development... Laboratoire Kastler Brossel ... etc. |
Bio-IT World
July 11, 2002
Malorye Branca |
Deep Sequence Diving Like sailors of old, genomic data miners dream of discovering riches and fame. Given the recent improvements in analytics -- and a little more time -- they just might succeed. |
Bio-IT World
Dec 2006/Jan 2007
John Russell |
Novartis' Answer to Harry Potter Imagine a magic wand able to instantly materialize novel, safe, and effective drugs. No such device exists, of course, but Novartis has a distant cousin of sorts: the UltraLink is an immensely powerful text-mining tool and knowledge management platform. |
Bio-IT World
May 2006
Kevin Davies |
Trailblazers Test Public Markets Three companies in postgenomic fields are going public. Infinity Pharmaceuticals, Perlegen Sciences, and Entelos announced they would be entering the public markets by means of merger, IPO, and institutional offering. |
Bio-IT World
February 10, 2003
Salvatore Salamone |
Made in Manhattan A talk with the new head of the Computational Biology Center at Memorial Sloan-Kettering. |
Bio-IT World
September 2006
Mike May |
Working Out the Flow Better management of workflow issues in biotech and pharma could change fundamental aspects of these sciences in the near future. |
Industrial Physicist
Jennifer Ouellette |
Bioinformatics moves into the mainstream An explosion of data is being tamed with new systems |
Bio-IT World
September 2005
John Russell |
Labor Pains and Gains Labor Day is the starting gun for the bio-science industry's race through the next year. Here are some up-and-coming items to watch: Transparency... Systems Biology... Crawford and McClellan... |
Bio-IT World
Dec 2006/Jan 2007
Giacomo Bastianelli |
The Future of Predictive Biology Predictive biology, data and the integration of disparate research disciplines are key ingredients for the future of drug discovery research and healthcare. |
Bio-IT World
March 17, 2004 |
Systems Biology: Top-Down or Bottom-Up? Systems biology involves the representation and analysis of an intact biological system. Like many of the technological developments over the past 20 years, such as genomics, proteomics, combinatorial chemistry, and bioinformatics, pharma and medical communities hold high hopes that systems biology will help move molecular research closer to the practice of medicine. |
Bio-IT World
June 12, 2002
John Dodge |
All Systems Go at ISB The Seattle-based Institute for Systems Biology (ISB), takes a holistic view of genomic and proteomic research. The author spoke with its president, noted biologist Leroy Hood, recently to find out how far ISB has come in its two years of life. |
The Motley Fool
March 4, 2011
Brian Orelli |
Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors. |
Bio-IT World
March 2007
Kevin Davies |
Leading by Example At Cambridge Healthtech Institute's annual Pharmaceutical and Biotech Leader's Summit, drug industry executives provided accounts of the profound organizational and technological changes that are helping organizations overcome industry-wide challenges. |
Bio-IT World
Jul/Aug 2006
Eric K. Neumann |
Combining Drug Toxicity Knowledge Nearly half the drugs entering clinical trials will fail because of some form of serious toxicity that was missed in preclinical studies. These failures should not happen at such a late stage in the process. So what can be done? |
Bio-IT World
May 9, 2003
Michael Greeley |
Mechanistic Models Investors are backing predictive modeling software that could speed drug development. |
| Knowledge@Wharton |
A New Approach to Valuing Biotech Stocks Enormous swings in biotechnology stock prices during the last few weeks show how difficult it is for investors to value biotech companies. It's important to understand the invisible potential locked up in the organizational structure of biotechnology companies... |
Bio-IT World
March 2006 |
Bio-IT World Bio-IT 50 The 50 companies profiled here have driven and continue to drive the future of biomedical research and drug discovery: Accelrys... Affymetrix.. Apple... Becton Dickinson... BlueArc... 454 Life Sciences... etc. |
Bio-IT World
August 2005
John Russell |
Pfizer's Model of Success Pfizer Global Research & Development began using sophisticated modeling technology and collaboration software to speed its race to a go-no-go decision on a cholesterol-lowering drug project. Killing the project sooner saved up to $2.8 million in costs and six months in delay. |
Bio-IT World
Dec 2006/Jan 2007 |
Resolute in the New Year Industry leaders in areas from pharmacogenetics to cheminformatics found 2006 to be a year of important steps forward, but looked with even more anticipation to 2007: Allen D. Roses, SVP, Pharmacogenetics GlaxoSmithKline... etc. |
Bio-IT World
April 2007
John Russell |
Toward a Cancer Interactome Researchers at the Center for Cancer Systems Biology are working toward identifying the high level wiring diagram for cancer. In this instance, that means an accurate map of all cancer-associated protein-protein interactions. |
Bio-IT World
January 21, 2005
Salvatore Salamone |
A Prescription for Information-Based Medicine TurboWorx president and CEO Jeff Augen not only combines computational and biology expertise, but also has a clear vision of how to advance life science discovery. |
Bio-IT World
January 21, 2005 |
Best Practices 2005: Strut Your Stuff Organizations are invited to strut their stuff for Bio*IT World's annual awards program. |
Chemistry World
January 2012 |
Cultivating collaboration A new network aims to bring the power of interdisciplinary innovation to bear on global food issues. |
Bio-IT World
Dec 2006/Jan 2007
Kevin Davies |
The NextBio Thing in Bioinformatics NextBio, which this fall officially introduced its platform after a year of beta testing by a handful of select organizations, aims to provide high-throughput information to researchers without them having to learn anything. |
Bio-IT World
Jul/Aug 2006
John Russell |
MathWorks Launches a 'Systems Biology' Tool The maker of the popular MATLAB programming environment recently launched a modeling product, SimBiology, aimed at systems biology and synthetic biology markets. |
HHMI Bulletin
Nov 2011
Sarah C.P. Williams. |
Carolyn Bertozzi: Changed Expectations Chemists trained in biology were once a rarity -- now they're becoming the norm. |
Bio-IT World
February 2007 |
Bio*IT World's Coming Attractions 2007 Bio-IT World Conference & Expo preview -- Meet the Keynotes... Oracle Users... Systems are Go... Candid Camera... A Vital IT Alliance... Next Generation Informatics... etc. |
| Chemistry World |
Fishing for Chemical Answers to Biological Questions James K. Chen talks about chemical biology, his love for the outdoors and fly fishing. |
Chemistry World
July 6, 2012 |
Protein power Tom Muir, professor of chemistry and molecular biology, Princeton University, US, is an expert in protein engineering and its application to studying cellular signalling networks. |
